Dietary Supplement Listing Act of 2026

This bill, the Dietary Supplement Listing Act of 2026, requires manufacturers, packers, or distributors of dietary supplements marketed in the United States to submit detailed information about their products to the Food and Drug Administration (FDA). This includes the supplement's name, label, ingredients (with amounts, though proprietary blend specifics remain confidential), serving sizes, warnings, and allergen statements. Existing supplements must be listed within 18 months of the bill's enactment, and new products before their market introduction, with a unique listing number required on labels after specified dates. The FDA will establish a public, searchable electronic database containing this information, excluding confidential business or proprietary blend details. Failure to comply with these listing requirements will result in the supplement being considered misbranded. The bill clarifies that it does not grant the FDA authority to approve dietary supplements prior to marketing.